Ankylosing spondylitis
Conference Coverage
Biologics boost work outcomes in axial spondyloarthritis
MAUI, HAWAII – Recent highlights in the epidemiology, imaging, and speedier diagnosis of axial spondyloarthritis.
Conference Coverage
Industry-funded rheumatology RCTs are higher quality
MAUI, HAWAII – An analysis of 20 years of rheumatology clinical trials.
Conference Coverage
Recent trials advance axial spondyloarthritis therapy
MAUI, HAWAII –
From the Journals
Venous thromboembolism risk elevated in ankylosing spondylitis patients
AS patients showed a significantly increased risk of VTE, compared with controls, especially during the first year after diagnosis.
From the Journals
TNF inhibitors improve BMD in ankylosing spondylitis
But the treatment did not improve vertebral fracture outcomes or radiographic progression.
From the Journals
Anti-TNFs slow SIJ damage in early axial spondyloarthritis
C-reactive protein and osteitis on MRI predict progression.
From the Journals
Back pain persists in one in five patients
Research finds four types of back pain trajectories, each associated with varying rates of pain, disability, and health care use.
From the Journals
CRP predicts anti-TNF response in ankylosing spondylitis
A baseline C-reactive protein level more than three times above the upper limit of normal correlated significantly with 12-week etanercept...
From the Journals
Back pain criteria perform well in patients with active axial psoriatic arthritis
The tool performed suboptimally overall, but had good sensitivity and specificity in patients with active symptoms.
From the Journals
Algorithm proposes approach for managing TNF inhibitor–induced psoriasis
News
FDA approves adalimumab biosimilar Hyrimoz
Hyrimoz is the third adalimumab biosimilar approved by the FDA.